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MECHANISTIC MODELS FIT TO ED001 DATA ON >40,000 TROUT EXPOSED
TO DIBENZO[A,L]PYRENE INDICATE MUTATIONS DO NOT DRIVE
INCREASED TUMOR RISK

Kenneth T. Bogen

䊐

Exponent Inc., Health Sciences

ED001-study data on increased liver and stomach tumor risks in >40,000 trout fed dibenzo[a,l]pyrene (DBP), one of the most potently mutagenic chemical carcinogens known,
provide the greatest low-dose dose-response resolution of any experimentally induced
tumor data set to date. Although multistage somatic mutation/clonal-expansion cancer
theory predicts that genotoxic carcinogens increase tumor risk in linear no-threshold proportion to dose at low doses, ED001 tumor data curiously exhibit substantial low-dose nonlinearity. To explore the role that nongenotoxic mechanisms may have played to yield such
nonlinearity, the liver and stomach tumor data sets were each fit by two models that each
assume a genotoxic and a nongenotoxic pathway to increased tumor risk: the stochastic 2stage (MVK) cancer model, and a model implementing the more recent dysregulated adaptive hyperplasia (DAH) theory of tumorigenesis. MVK and DAH fits to the data sets were
each excellent, but unexpectedly each MVK fit implies that DBP acts to increase tumor risk
by entirely non-mutagenic mechanisms. Given that DBP is such a potent mutagen, the
MVK-model fits obtained appear to be biologically implausible, whereas the DAH-model
fits reflect that model’s assumption that chemical-induced tumorigenesis typically is driven
by elevated repair-cell populations rather than mutations per se.
䊐
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INTRODUCTION

A default linear no-threshold (LNT) approach to extrapolate
increased cancer risks from environmental chemical carcinogen exposures has been applied by the U.S. Environmental Protection Agency
(EPA) over the last 45 years, particularly (more recently) for carcinogens
known or assumed to have a genotoxic mode of action (MOA). The LNT
approach has always been based explicitly on the hypothesis that critical
DNA mutations are key, rate-limiting events that can drive tumorigenesis,
in accordance with the multistage somatic mutation theory of cancer
(U.S. EPA 1976, 1986, 2005, 2007; Anderson et al. 1983). A stochastic twostage/clonal-expansion version of this model was proposed originally by
Armitage and Doll (1957), shortly after Watson and Crick deciphered the
structure of DNA and basic elements of genetic machinery were being
elucidated. This model posits that a rare, critical somatic mutation can
transform a normal “stem” cell (i.e., any cell not terminally differentiat-
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ed that is capable of dividing) into a premalignant cell that tends to proliferate over time, and another such mutation can transform any premalignant cell into a tumor cell. This two-stage/clonal-expansion model was
later refined by Moolgavkar, Venzon, Knudson (MVK) and others
(Moolgavkar and Venzon 1979; Moolgavkar and Knudson 1981;
Moolgavkar 1983, 1988; Moolgavkar et al. 1988, 1989; Moolgavkar and
Luebeck 1990; Leubeck et al. 1999), who obtained the exact algebraic
solution that arises if this model is represented as a doubly stochastic
Poisson process with parameters that are piecewise-homogeneous over
any k time intervals.
According to the somatic-mutation/clonal-expansion theory, agents
can increase tumor risk not only by causing mutations, but also (or solely) by increasing the number of premalignant cells that are at risk for
undergoing malignant transformation by a dose-induced (or spontaneous background) mutation. It has thus become recognized that LNT
cancer risk extrapolation is likely to be conservative even for genotoxic
chemical carcinogens, to the extent that they happen also to increase
tumor risk by inducing net premalignant-cell proliferation and/or genotoxic endpoints at tumorigenic doses, in the case that each such endpoint
also happens to have a substantially nonlinear or threshold dose-response
(NRC 1994; Bolt et al. 2004; O’Brien et al. 2006). However, if tumorigenesis requires one or more critical somatic mutations that can be induced
in linear proportion to dose (as assumed by the somatic mutation theory
of cancer and implementations of it, such as the MVK mode), then by definition a linear, mutagenic-potency coefficient in dose must dominate at
very low doses. Consequently, for potently mutagenic chemical carcinogens, an LNT dose-response relationship for increased cancer risk is widely assumed to be both scientifically plausible and reasonably likely.
The ED001 (“mega-trout”) ultra-low-dose bioassay generated detailed
data on elevated liver and stomach tumor incidence observed in a total of
>40,000 trout, eight groups of which were exposed to concentrations
ranging from 0 to 225 ppm of dibenzo[a,l]pyrene (DBP) in food for four
weeks, followed by normal diet for nine months (Bailey et al. 2009;
Williams et al. 2003; 2009). This was and remains the largest single cancer
bioassay study ever done, which generated the highest resolution set of
tumor dose-response data, of any bioassay ever conducted using any type
of experimental animal. The ED001 study design took advantage of the
fact that trout are a flexible and established model of animal carcinogenesis that can be applied efficiently, using relatively large numbers of individual animals (Dashwood et al. 1999; Reddy et al. 1999a b; Williams et al.
2003, 2009; Benninghoff et al. 2012).
The “model genotoxic” chemical and “tumor initiator” used in the
ED001 study, DBP, is one of the most potently mutagenic chemical carcinogens known (Higginbotham et al. 1993; Busby et al. 1995; Prahalad et
387
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al. 1997; Chakravarti et al. 1995; 2000; Williams et al. 2003; Mahadevan et
al. 2005; Plísková et al. 2005; Mourón et al. 2006; DeMarini et al. 2011;
Guttenplan et al. 2012). DBP requires metabolic activation by species-specific cytochrome P450 enzymes to generate DNA adducts, mutations,
chromosome damage, and tumors (Buters et al. 2002; Schober et al. 2006;
Kushman et al. 2007; Lagerqvist et al. 2008; Topinka et al. 2008; Meschini
et al. 2010). From additional analyses done on stomach-tissue samples in
the ED001 study, Bailey et al. (2009) concluded that there was “clear evidence from stomach tumors that DBP-driven mutations in the Ki-ras
oncogene were present even at low dose.” In Big Blue mouse cells
exposed to diol-epoxide metabolites of DBP for 30 min in vitro, both DBPDNA adducts and cII mutations increased in approximate proportion to
exposure concentration (Yoon et al. 2004). Such approximate proportionality was also observed between exposure-induced lacZ mutations and
bulky DNA adducts measured in different tissues of groups of 25-week-old
male transgenic MutaTMMouse mice dosed daily with the DBP-related
polycyclic aromatic hydrocarbon, benzo(a)pyrene (BaP) (Lemieux et al.
2011). BaP-DNA-adduct levels measured in those mice were highest in
glandular stomach and liver, which Lemieux et al. ( 2011) pointed out
were sites of first BaP contact and of primary BaP metabolism, respectively—factors also likely to have applied to the DBP that was administered in food to ED001-study trout that exhibited exposure-induced
tumors in the same two target tissues.
Because DBP is one of the most potently mutagenic carcinogens
known, it is surprising that ED001 dose-response data on liver and stomach
tumors in DBP-exposed fish were reported to exhibit substantial nonlinearity at low doses (Williams et al. 2003; Bailey et al. 2009). Bailey et al.
(2009) concluded that, among nine statistical/regression-type risk models explored, three models (linear probit, quadratic logit, and Ryzin-Rai)
that each fit the ED001 liver tumor data well predicted increased risks that
fell increasingly below default benchmark-dose-type regulatory extrapolation assumptions with decreasing DBP dose, that low-dose tumor
response was not predictable from hepatic DBP-DNA adduct biomarkers,
and thus that ED001 data provided the first experimental demonstration
that EPA default LNT assumptions for genotoxic carcinogens are inherently conservative. Specifically, observed log liver-tumor likelihood and
corresponding log DBP concentration were found to exhibit a substantially nonlinear (i.e., >1) slope of ~2.3 that was significantly greater
(p = 0.0007) than that of ~1.3 exhibited between the log of the number
of bulky DBP-DNA adducts measured in liver and log DBP concentration
(Bailey et al. 2009). However, goodness-of-fit values for these relationships
were not reported, mechanistic cancer models were not applied, and specific mechanistic hypotheses consistent with ED001 study data were not discussed.
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It is possible that, due to DBP-induced cytotoxicity, DBP may act with
a dual MOA to increase tumor risk via a combination of mutagenic and
nongenotoxic-promotion mechanisms. For example, DBP can potently
transform cells in vitro even in the absence of detected DNA adducts
(Nesnow et al. 1997; 2000). DBP can also reduce clonogenic survival by
triggering cytoxicity and apoptosis, as well as trigger cell proliferation, particularly at DBP or DBP-metabolite concentrations exceeding 10 to 100
ppb in several cell types studied in vitro (Busby et al. 1995; Nesnow et al.
1997; Yoon et al. 2004; Plísková et al. 2005; Schober et al. 2006; Kushman et
al. 2007; Topinka et al. 2008) and in livers of trout exposed to DBP in vivo
5 days/week for four weeks (Zipperman 1999). Tumor-response patterns
observed in the ED001 study may therefore be consistent with predictions
made by a biologically based, mechanistic cancer-risk model that accounts
explicitly for dual-MOA pathways of tumorigenesis.
The specific aim of the present study was to examine the dual-MOA
hypothesis for DBP quantitatively, using the biologically based, mechanistic MVK cancer model that explicitly incorporates separate mutagenic
and premalignant-cell-proliferation pathways to increased levels of predicted tumor risk. Specifically, the MVK model was fit to ED001 doseresponse data on liver and stomach tumor incidence in DBP-exposed
trout, and relative impacts associated with best estimates of MVK parameters governing mutation and those governing premalignant-cell proliferation were calculated for each tumor endpoint.
For comparison, the ED001 data were also fit to a biologically based,
mechanistic cancer risk model that differs fundamentally from the MVK
model, by predicting that tumorigenic exposures, including those involving potent mutagens, typically act to increase tumor risk predominantly
or virtually exclusively by increasing not mutation rates, but rather the
number of cells engaged in adaptive hyperplasia (AH) in response to
exposure-induced cytotoxic stress. Specifically, the “dysregulated AH”
(DAH) model (Figure 1) assumes that incipient tumors arise when a stem
cell that has been recruited into a (normally rare) somatically propagated AH state or program (such as that normally invoked to regenerate or
repair injured or infected tissue), also contains a rare DNA mutation that
blocks the normal ability of an AH-state cell to terminate AH (Bogen
2013). The DAH model is thus a one-step, state-dependent model of
tumorigenesis. Because tissue repair and regeneration normally occur
only sporadically throughout life, the DAH model implies that the pool
of cells that most readily generate tumors is typically relatively small, but
subject to periodic expansion and contraction (Bogen 2013). In contrast,
the MVK model assumes that all stem cells in each tissue are susceptible
to tumorigenic mutations.
Details concerning the ED001 data that were fit, specific mathematical
model representations, and fitting procedures are described in Methods.
389
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FIGURE 1. Stress-dependent tumorigenic pathways posited by the “dysregulated adaptive hyperplasia” (DAH) theory (Bogen 2013). Two types of stress (downward green “Sublethal stress” and “Cell
killing” arrows) transform normal stem cells (N) to protective (P) or regenerative (R) phenotypes,
respectively, epigenetically maintained by corresponding microRNA-expression profiles. A critical
somatic mutation mB or mM (horizontal black dashed arrows) can transform an N-cell to one that is
potentially prebenign (NB) or potentially premalignant (NM), respectively, or likewise can transform
P- or R-cells to corresponding prebenign (PB) or premalignant (PM) proliferative cells. The critical
mutation prevents normal transduction (blue “Resolution” arrows) of a tissue-specific signal required
to resolve stress-induced P- or R-type adaptive hyperplasia. Conditional on surviving immune surveillance, net proliferation yields slow or more rapid clonal expansion of PB or PM cells, respectively.
Surviving PB clones are benign tumors. Similar to mammalian cells in tissue culture, PM clones
inevitably undergo telomere crisis, after which each surviving cell is an incipient malignant tumor
cell.

Results obtained are then presented, followed by a discussion that interprets these results and their implications for future related research.
METHODS
Bioassay Data

To explore dose-response down to a targeted 10 excess liver tumors
per 10,000 animals (ED001), a total of 40,800 Shasta strain rainbow trout
fry (Oncorhynchus mykiss), initially at ~1.5 g body weight, were administered
Oregon Test Diet (OTD), or OTD mixed with 0.450, 1.27, 3.57, 10.1, 28.4,
80.0, or 225 ppm DBP for 4 weeks, then were fed control diet for 9 months
(Bailey et al. 2009). The incidence of stomach and liver tumors was recorded during exposure, the 9-month post-exposure period, or sacrifice at ~12
±0.5 months. Based on reported body weight, the exposure period was
modeled to occur during month three of the 12-month exposure period
(FAO 2011). Separate enumeration of benign vs. malignant tumors was
not provided (Bailey et al. 2009, Tables 1 and S1), but data from similar
studies indicate that potent genotoxic polycyclic aromatic hydrocarbons
such as aflatoxin B1 and DBP can elicit predominantly malignant tumors
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(Reddy et al. 1999a; Williams 2012). Data from each set of four separate
groups of trout that were administered the same dose were combined into
one group per dose, and corresponding dose-specific chi-square tests were
performed to test for consistency with binomial sampling error of tumor
counts within each dose group. Only liver tumors in the 28.4-ppm dose
group failed this test (p < 10–6), and a corresponding extended Fisher
exact test (p < 10–5) (Baglivo et al. 1988), and for this dose group, the standard error was taken to be the empirical standard deviation (0.0759) of
the four corresponding observed incidence rates.
Dose-Response Models

The MVK (two-stage doubly stochastic clonal-expansion) model of
cancer risk posits that a critical oncogene mutation occurring at rate m1
causes a transition from a normal stem cell (N) to a stage-one or premalignant cell (P), and another mutation occurring at rate m2 causes a transition of a P cell to an incipient cancer cell (M). N- and P-cells undergo
processes of birth at rates b0 and b, respectively, and loss at rates d0 and d,
respectively (via death or terminal differentiation), which may be affected
by endogenous or xenobiotic exposures, with b > d (positive net proliferation) being characteristic of P-cells (Moolgavkar 1983; Moolgavkar et al.
1988; Moolgavkar and Luebeck 1990). In view of the brief periods of exposure and follow-up, it was assumed for simplicity that N is constant (as an
effective time-weighted average scaling factor), b0 ≈ d0 (steady-state tissue
maintenance) for N-cells, and the product v = N m1 was fit to each control
tumor incidence rate. Assuming that DBP acted as a pure mutagen, the
MVK model was evaluated with parameters mi = m0(1 + qi C(t)), (for
i = 1,2), assuming m0 = 10–6 (representing a single background mutation
rate), b = g, and d = d0, where qi denote “potency” coefficients for DBPinduced mutations), and C(t) = DBP concentration in ppm at time t (measured in months), with C(t) = 0 if t ≤ 2 or t > 3. Assuming alternatively that
DBP is a purely non-mutagenic tumor promoter that acts only to increase
the net rate of proliferation of premalignant cells, the MVK model was
evaluated with parameters mi = m0 (for i = 1,2), and b = g(1 + q1 C(t))
exp(–q2 C(t)) + d, and d = d0, where q1 and q2 here denote potency and
potency-attenuation coefficients, respectively, for DBP-induced net proliferation of P-cells, and q2 > 0 was assumed only for liver tumors to better
model the non-monotonic response pattern observed for that tumor endpoint. Fits using an MVK model parameterized to reflect a dual MOA,
involving DBP-induced elevations both in mutation rates and in net rates
of premalignant-cell population growth, were also explored (see Results).
To simplify DAH-model implementation, in view of the driving role of
transient production of all preneoplastic (PB and RM) cells in proportion
to the total duration of AH-generating stress that is predicted by the DAH
model (see Introduction), and the fact that tumor histology information
391
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was not reported by Bailey et al. (2009) as noted above, tumors were all
assumed to be malignant. In the absence of time-to-tumor data, this
assumption did not clearly constrain modeling results to predict responses that differ substantially from those that could be obtained by modeling
separate benign and malignant DAH pathways. The DAH model was
implemented by adapting the MVK (two-stage, doubly stochastic Poissonprocess) model to reflect a characteristic DAH-specific parameter structure. Specifically, the MVK-model parameters were adapted as follows: N
= 1, m1 = m0[1 + q1 C(t) exp(–d C(t))] {1 + 103 q2 Φ([ln(C(t)) –
ln(μ)]/ln(σg))} with d = 2 q1 (liver) or d = 0 (stomach), m2 = 10–3, b = 1, d
= 3/4 or 1/2 (for liver or stomach, respectively), where qi denote hypothetical linear (i = 1) and nonlinear (i = 2) potency coefficients for DBPinduced regenerative AH, Φ = the standard normal cumulative probability distribution function (cdf), and ln = natural logarithm. Increased
tumor risk due to DBP-induced AH was thus assumed to reflect a dominant pathway requiring the interaction of a mutation event, assumed to
occur at a rate proportional to q1 C(t), and the size of the regenerative
AH-cell population in each target tissue, assumed to be proportional to a
cumulative lognormal function of concentration C(t) with a median
response at C(t) = μ and a geometric standard deviation of σg. The DAH
model was first fit to both ED001 data sets conditional on q1 = 1/200 (chosen arbitrarily); additional fits to stomach-tumor data were obtained
using three additional values of q1 in the range 0 ≤ q1 ≤ 1/10 to demonstrate that DAH-model goodness of fit is effectively independent of q1
within this range (see Results).
Calculations and Statistical Analysis

The significance of tumor-incidence elevation observed in each exposure group compared to controls was assessed by Fisher exact test. The
MVK and DAH models described were evaluated numerically by the
method of Crump et al. (2005) to evaluate predicted cumulative probability R(C) of observing each tumor type at time t = 12 months after exposure to DBP concentration C during period 2 ≤ t < 3 (see Appendix). All
four models were fit by inverse-variance weighted Levenberg-Marquardt
minimization of a chi-square objective function comparing the fitted to
observed tumor incidence rates, assuming binomial sampling errors
(except as noted above for liver tumor counts in the 28.4-ppm concentration group), and associated covariances were used to calculate asymptotic chi-square goodness-of-fit statistics (Press et al. 1986). Additionally,
low-dose data subsets for each tumor type were each tested for approximate linearity of dose-response using a corresponding chi-square goodness-of-fit statistic from inverse-variance-weighted linear regression.
Biologically based model predictions of increased tumor-specific risk
above background were compared graphically. For this comparison,
392
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increased risk A(C) to DBP-exposed trout above background risk R(0) for
each tumor type was extrapolated at low doses using each well-fitting biologically based model, assuming that R(0) arises independent of DBP
exposure: i.e., assuming that A(C) = [R(C)–R(0)]/[1–R(0)]. For the
DAH model applied to stomach tumors, an exact expression for the limiting value of A(C) as C tends to zero was obtained by symbolically evaluating the (quite complicated) exact analytic expression obtained for the
corresponding MVK model evaluated at time t = 12, after a total of k = 3
periods each involving constant model-parameter values, using the piecewise-recursive formula derived by Moolgavkar and Luebeck (1990) for
risk R(C) conditional on k.
All numerical calculations and symbolic (including algebraic, derivative, and limit) calculations were performed using Mathematica® 9.0 software (Wolfram Research 2013). P-values <10–10 were indicated as being
~0.
RESULTS

Compared to control-group incidence rates by Fisher exact tests, liver
tumors were not elevated significantly at the lowest two DBP concentrations
used in the ED001 study (p ≥ 0.39), but were clearly elevated (p = 10–9) in
the third-highest (3.57-ppb) DBP-exposure group that had a liver-tumor
incidence rate of 0.82%, as well as in all higher dose groups (p = ~0).
Similar pairwise comparisons showed that stomach tumors were not elevated significantly at the lowest three DBP concentrations used (p ≥ 0.39),
were marginally elevated (p = 0.061) in the third-highest exposure group,
were significantly elevated (p = 0.020) in the forth-highest (10.1-ppb)
DBP-exposure group that had a stomach-tumor incidence rate of 0.51%,
as well as in all higher dose groups (p = ~0).
Table 1 lists parameter estimates from fits to data on liver and stomach tumors in ED001-study trout obtained using the biologically based,
mechanistic MVK and DAH models, together with goodness-of-fit statistics. Neither the purely genotoxic MVK model nor the MS2 model are
plausibly consistent with either set of tumor data (p = ~0), whereas good
(p = ~0.5) and nearly identical fits to data on each tumor type were
obtained using the purely nongenotoxic MVK model and the DAH
model. The purely nongenotoxic MVK and DAH model fits are compared in Figure 2. Fits of the MVK model parameterized initially to reflect
a dual MOA (i.e., both genotoxic and nongenotoxic pathways to
increased tumor risk) converged on the pure nongenotoxic MVK fits listed in Table 1, so the latter fits represent the best MVK-model fits obtained
to ED001 data on each tumor endpoint.
Figure 3 plots tumor- and model-specific increased risks predicted by
the nongenotoxic (pure-promoter) MVK model (blue curves), and by the
DAH model (black curves). In this figure, the fit to liver-tumor data
393
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DAH
DAH
DAH
DAH

Model typea
MVK G
MVK G
MVK N
MVK N
DAH
DAH

2.21 (0.284)
2.23 (0.287)
2.23 (0.288)
2.23 (0.289)

N m0 or p0
0.437 (L)
1.68 (L)
1.10 (1.43)
1.14 (1.40)
5.95 (1.04)
2.24 (0.287)
1 (–)
1 (–)
1 (–)
1 (–)

g or b
0 (–)
0.426 (L)
0.455 (0.158)
0.509 (0.151)
1 (–)
1 (–)
1/2 (–)
1/2 (–)
1/2 (–)
1/2 (–)

d
0 (–)
0 (–)
56.9 (86.5)
23.9 (36.1)
3/4 (–)
1/2 (–)
1/10 (–)
1/40 (–)
1/1000 (–)
0 (–)

q1
1160. (L)
2.28 (L)
0.139 (0.071)
0.0276 (0.0115)
1/200 (–)
1/200 (–)
0.167 (0.0270)
0.626 (0.108)
6.92 (2.62)
11.5 (5.57)

q2
0 (–)
12.9 (L)
0.00471 (0.0049)
–
4.49 (0.923)
2.50 (0.560)
58.9 (8.51)
78.4 (12.2)
270 (107)
384 (194)

μ
–
–
–
–
65.0 (9.20)
141 (30.2)

2.38 (0.285)
2.39 (0.241)
2.93 (0.382)
3.13 (0.460)

σg
–
–
–
–
3.19 (0.271)
2.58 (0.251)

4
4
4
4

dfc
6
4
3
4
4
4

0.57
0.52
0.53
0.54

P-valuec
~0
~0
0.052
0.67
0.15
0.51

G = purely genotoxic; N = purely nongenotoxic. For the DAH model, the parameter d was pre-assigned, not optimized; two different values were inadvertently
assigned for the two tumor types. See text for model-type definitions. Parameter and SE estimates listed for DAH parameter p0 are (in order to fit these in this table)
1000-fold greater than the corresponding estimates actually calculated.
b
SE = standard error; – = parameter not applicable; (–) = SE not calculated (parameter set to a constant); L = SE >2 times the parameter-value estimate x; if SE
> x, the listed model parameter is likely not identifiable (i.e., as good a fit may be possible using fewer parameters). Estimated parameter values listed each show
three significant digits; assumed constants listed show infinite precision.
c
df = degrees of freedom for chi-square goodness of fit test associated with the indicated p-value.

a

Stomach
Stomach
Stomach
Stomach

Tumor type
Liver
Stomach
Liver
Stomach
Liver
Stomach

Model parameter estimate (SE)b

TABLE 1. MVK and DAH model fits to ED001 study data on liver and stomach tumors in >40,000 DBP-exposed trout.
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FIGURE 2. Nongenotoxic or “pure promoter” MVK model (blue curves) and DAH model (balck
curves) fit to ED001 “mega-trout” study data (open points) on the incidence of liver tumors (solid
curves) and stomach tumors (dashed curves) in Shasta strain trout fry fed different concentrations
of DBP for four weeks, then followed on control diet for nine months before sacrifice. Error bars
denote ±1 SE.

FIGURE 3. Each of the risk models plotted in Figure 2 in relation to the tumor data is re-plotted here
with the Y-axis re-expressed as increased tumor risk over each corresponding background risk estimated to occur in the absence of DBP exposure. The DAH-model fits each involve a parameter q1
that defines assumed mutagenic potency. A q1 value of 0.005 was assumed for the DAH-model fit to
liver-tumor data (blue dashed curve). Four different values of q1 (including 0.005, as indicated) were
used to obtain four corresponding fits to stomach-tumor data (dotted black curves).

shown (blue dashed curve) assumed a value of 0.005 for the DAH-model
parameter q1, which specifies the potency with which DBP is assumed to
increase the critical DAH-mutation rate. To obtain the four DAH-model
fits to stomach-tumor data shown (as black dotted curves) in Figure 3,
395
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four different corresponding values of q1 were assumed (including the
value q1 = 0.005) as indicated in the figure. At very low DBP concentrations (< ~1 ppm) administered for four weeks, the fits to liver- and to
stomach-tumor data that were made using the purely nongenotoxic MVK
model are ~550-fold and ~120-fold greater, respectively, than those made
using the DAH model conditional on q1 = 0.005. Figure 3 illustrates how
the magnitude of this MVK-to-DAH ratio of predicted, model-specific
increased risk is directly and linearly proportional to the assumed value
of the DAH-model parameter q1.
As values of maximum DBP concentration C = Max[C(t)] approach 0,
the terms involving exp and Φ in the DAH-model expression given in
Methods clearly reduce to 1 and 0, respectively. Conditional on this simplification, analysis (as described in Methods) of the DAH model yielded
the following corresponding exact expression for increased risk A(C) as
a function of C in the limit as C→0, as a function of model parameters m0
and q1:
A(C) = {(r1/2000) – ln[(r2 + r1 X)/(r2 + r1 X9/10)]}m0 q1 C
= ~0.16011 m0 q1 C,

(1)

where r1 = R–c, r2 = R+c, R = 253001 , c = 499, and X = exp(R/100) (see
Appendix). As illustrated in Table 1 for DAH fits to the stomach tumor
data, when DAH-model parameters are re-optimized using different values of q1 in the range 0 ≤ q1 ≤ 1/10, all the resulting fits are good and virtually identical within the range of the data. Each such fit involves a virtually identical value of m0, which essentially fits the background tumor
rate. Optimizing the two lognormal parameters contained in the DAH
model thus generates the good fit achieved to all the non-background
data for each tumor type. Numerical evaluations of the DAH model that
was fit to stomach-tumor data show that for all C ≤ 0.1 ppm, Equation 1 is
accurate to within ~2.5% for all q1 ≤ 1/10 and to within ~0.5% for all q1
≤ 1/40. Because models found to fit well to data on both tumor endpoints
(Table 1) are structurally similar, analogous results are expected concerning how well Equation 1 approximates DAH-model fits to data on
liver tumors, conditional on similar ranges for the values of q1 and C.
Consequently, the DAH model applied essentially combines a lognormal
dose-response model that dominates at higher doses, together with a
“hockey-stick”-type model that dominates at much lower doses, over
which the limiting linear “hockey-stick” dose-response slope is determined entirely by the mutagenic-potency parameter q1 (Figure 3).
Stepwise chi-square goodness-of-fit tests for consistency with doseresponse linearity, each performed on a tumor-specific dose-response
data subset consisting of the k lowest-concentration data points, showed
that the liver-tumor data subset, including the 3.57-ppm exposure group
396
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exhibiting a 0.82% rate of liver-tumor incidence, was found to be only
marginally consistent with linearity (k = 4, p = 0.054); all larger subsets of
the concentration-ordered liver-tumor data (i.e., those including the
10.1-ppm exposure group exhibiting a 5.5% rate of liver-tumor incidence) were clearly inconsistent with linearity (k ≥ 5, p < 10–8). Doseresponse linearity was thus determined to be plausible only for rates less
than 2% of that observed for liver tumors in the highest DBP-concentration group studied.
Dose-response linearity for DBP-induced stomach tumors was likewise
determined to be rejected only when the third-highest dose group (4.6%
of which developed stomach tumors) was included (k = 6, p = 0.00015).
Dose-response linearity was thus determined to be plausible only for rates
less than ~6% of that observed for stomach tumors in the highest DBPconcentration group studied.
DISCUSSION AND CONCLUSIONS

Results from the present study show that the two biologically based,
mechanistic models of tumorigenesis (MVK and DAH) examined each
provide good fits to liver- and stomach-tumor incidence data from the
ED001 study. Surprisingly and counter-intuitively, however, the good MVK
model fits obtained that are listed in Table 1 all assume a purely nongenotoxic MOA, in each case with zero predicted contribution from exposureinduced mutations by one of the most potently mutagenic carcinogens
known. The nongenotoxic MVK model applied expresses increased net
proliferation of premalignant cells as a linear function of DBP concentration. Nevertheless, predictions made by this model were found to be
consistent with a lognormal pattern of observed responses in relation to
DBP concentration that is exhibited by the DAH model that was fit to the
same tumor data.
The observation that nongenotoxic MVK-model fits listed in Table 1
are each statistically consistent with the data to which these models were
fit, while corresponding genotoxic MVK-model fits are not plausibly consistent with those data, does not prove that DBP-induced mutations
played no role in elevating tumor incidence in the ED001 study. As noted
in Results, a low-dose subset of each tumor-specific data set is clearly statistically consistent with an LNT dose-response. Even if none of the data
were determined to be statistically consistent with low-dose linearity, from
a statistical standpoint, it is a well-recognized practical impossibility to disprove that an LNT dose-response does not actually occur at sufficiently
low doses for any endpoint, particularly if it occurs spontaneously at a
non-negligible rate, even using tens of thousands of experimental animals as done in the ED001 study. However, as also noted in Results, each
subset of ED001-study data found to be consistent statistically with low-dose
linearity was also found to be rather limited, representing very small frac397
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tions—less than about 2% and 6%—of the maximum rates of incidence
observed for liver and stomach tumors, respectively. These are rather
small upper statistical bounds on the plausible contribution of low-dose
linearity to tumor rates increased by exposure to DBP, one of the most
potently mutagenic carcinogens known.
Forward mutations are potently induced by DBP, and are readily
detected in animal cells in vitro and in vivo as approximately linear functions of exposure, even at concentrations that are at most marginally cytotoxic (see Introduction). Therefore, if the somatic-mutation/MVK model
of cancer is valid, MVK-model fits obtained to ED001-study tumor data
should have involved estimated increases above background mutation
rates, and corresponding low-dose dose-response linearity over response
ranges that extend beyond merely marginal elevations above background
tumor rates. This expectation is clearly inconsistent with the modeling
results obtained for liver tumors discussed, and possibly also with those
for stomach tumors, even after addressing plausible bounds on statistical
uncertainty that pertains to the lowest portions of each observed tumor
dose-response pattern. Thus, while MVK-modeling results were obtained
that are statistically consistent with ED001-study tumor data, the results do
not appear to be biologically plausible because they imply that DBPinduced mutations played implausibly small or even no role in tumorigenic effects that were potently elicited by DBP exposure.
Like the MVK model, the mechanistic DAH model also assumes that
mutation plays a critical, rate-limiting role in tumorigenesis. However, the
DAH model places no lower bound on the assumed positive magnitude
of this role. If the single critical mutation posited by the DAH model for
each tumor type is typically extremely rare, then this model predicts that
elevated tumor incidence after sustained chemical exposure can arise primarily (or solely) by an associated increase in the number of cells recruited into AH-cell populations that, according to this model, most typically
are the source of exposure-induced tumors. The DAH model thus provides one example of a mechanistic, biologically based model of tumorigenesis that happens to provide good fits to ED001 tumor data, based on
modeling assumptions that are consistent with data concerning different
toxic cellular effects of DBP. However, the fact that good DAH-model fits
were obtained, of course, may instead simply coincidentally reflect the
approximate lognormal pattern that happens to be exhibited by both
tumor types that were elevated by DBP in the ED001 study.
At very low DBP concentrations (less than about 1 ppm) administered
for four weeks, the fits to liver- and to stomach-tumor data obtained using
the purely nongenotoxic MVK model were determined to be ~550-fold
and ~120-fold greater, respectively, than those obtained using the biologically based, mechanistic DAH model conditional on a value of 0.005 for
the DAH-model parameter q1 (Figure 3). The magnitudes of these rela398
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tive differences in predicted increased risk are effectively arbitrary,
because Equation 1 (see Results) implies that these relative differences in
predicted increased risk are linearly proportional to the value of the q1
parameter used to implement the DAH model, over a fairly large q1-range
bounded by zero. As noted in Results, the DAH model thus exhibits a
dose-response pattern that combines an “arbitrary-slope hockey-stick” at
low doses, with a lognormal S-shaped response at higher doses. Thus
when DAH-model fits to each tumor set are conditioned on different values of q1, the goodness of fit remains virtually unaffected, but the “slope”
of the low-dose hockey-stick part of the fit is re-scaled in proportion to q1.
When the Y-axis is log-transformed as in Figure 3, this re-scaling of slope
appears as a vertical shift of the low-dose portions of the fitted (dotted
black) curves (i.e., the portions at which DBP concentration is less than
~1 ppm), which each have unit slope on a log scale.
The ED001 “mega-trout” bioassay offers the greatest statistical power
currently available to resolve different low-dose dose-response relationships for tumors induced by a genotoxic chemical carcinogen. Substantial
(>10-fold) improvement in statistical power in this regard is unlikely to
arise for years or perhaps decades. Consequently, a direct experimental
test between low-dose dose-response predictions made, for example, by
the DAH vs. the MVK model using animal bioassay data, is not feasible
either currently or perhaps even within the next decade. At this point,
such a comparison can be made only by generating additional experimental data and by improving theory concerning fundamental molecular mechanisms of tumorigenesis. Such developments thus continue to be
the long-recognized key to improved risk assessment for environmental
chemical carcinogens (Albert 1994).
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APPENDIX

All MVK and DAH models fit were implemented numerically as the
solution for predicted cumulative likelihood R(t) that a malignant cell
appears by time t = 12 months for a general MVK model expressed in
terms of the parameters v(t), m2, b(t), and d, which were defined in
Methods in fundamentally different ways for each model considered, as
indicated where applicable as functions of time t. Crump et al. (2005)
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showed that a general solution for R(t) = 1 – C(t, t), can be evaluated by
numerically solving the following linked system of ordinary differential
equations involving three auxiliary variables (A, B, and C) each a function of starting time s and ending time t, with 0 ≤ s ≤ t:
dA(s, t)/dt = b(t–s) A2(s, t) + d – [b(t–s) + d – m2]A(s, t)

(A-1)

dB(s, t)/dt = 2b(t–s) A(s, t) B(s, t) + d
– [b(t–s) + d – m2]A(s, t)

(A-2)

dC(s, t)/dt = v(t–s) C(s, t) [A(s, t) – 1],

(A-3)

with initial conditions A(0, t) = C(0, t) =1 and B(0, t) = –m2. For piecewiseconstant parameters, R(t) can also be solved analytically (see below).
From the general analytic solution by Moolgavkar and Luebeck
(1990) defining R(t) for an MVK model with piecewise-constant parameters during intervals 0 ≤ t < 2, 2 ≤ t < 3, and t ≥ 3, the exact value of R(t)
for the DAH model described in Methods with parameters v = ~m0(1 + q1
C) for very small maximum DBP concentration C, m2, b, and d is given by
R(t) = 1 – exp[–(m0/b) {A + F ln(S2/S3)
+ ln[B S3/(2 r S2)]}],

(A-4)

where A = (h–r)F/2, h = b–d–m2, r = [(b+d+m2) – 4 b d]1/2, F = 1 + q1 C, B
= (r+h) + (r–h)Xt, X = exp(r), Si = r + b – d – m2 + (r – b + d + m2)Xt–i, t =
12, i = 1,2, and ln denotes natural logarithm. Mathematica 9.0® symbolically calculated the derivative of increased risk A(C), defined in Methods,
with respect to C in the limit as C→0 as
LimC→0[dA(C)/dC] = {[b – d – m2 – r
+ 2 ln(S2/S3)]/(2 b)} m0 q1 ,

(A-5)

which, using definitions given above and multiplying by C, yields
Equation 1 (in Results) after substituting values of m0, m2, b, and d defined
in Methods for the DAH model.
REFERENCES
Albert R. 1994. Carcinogen risk assessment in the U.S. Environmental Protection Agency. Crit Rev
Toxicol 24(1):75–85.
Anderson EL, Albert RE, McGaughy R, Bayard S, Bayliss D, Chen C, Chu M, Gibb H, Haberman B,
Hiremath C, Singh D, and Thorslund T. 1983. Quantitative approaches in use to assess cancer
risk. Risk Anal 3(4):277–295.
Armitage P, and Doll R. 1957. A two-stage theory of carcinogenesis in relation to the age distribution
of human cancer. Br J Cancer 11:161–169.

400

Published by ScholarWorks@UMass Amherst, 2014

15

Dose-Response: An International Journal, Vol. 12 [2014], Iss. 3, Art. 5

Models Fit to ED001 Tumor Data
Baglivo J, Oliver D, and Pagano M. 1988. Methods for the analysis of contingency tables with large
and small cell counts. J Am Statist Assoc 83:1006–1013.
Bailey GS, Reddy AP, Pereira CB, Harttig U, Baird W, Spitsbergen JM, Hendricks JD, Orner GA,
Williams DE, and Swenberg JA. 2009. Non-linear cancer response at ultra-low dose: a 40,800-animal ED001 tumor and biomarker study. Chem Res Toxicol 22:1264–1276.
Benninghoff AD, Orner GA, Buchner CH, Hendricks JD, Duffy AM, and Williams DE. 2012.
Promotion of hepatocarcinogenesis by perfluoroalkyl acids in rainbow trout. Toxicol Sci
125(1):69–78.
Bogen KT. 2013. Efficient tumorigenesis by mutation-induced failure to terminate microRNA-mediated adaptive hyperplasia. Med Hypoth 80:83–93.
Bolt HM, Foth H, Hengstler JG, and Degen GH. 2004. Carcinogenicity categorization of chemicalsnew aspects to be considered in a European perspective. Toxicol Lett 151(1):29–41.
Busby WF Jr, Smith H, Crespi CL, and Penman BW. 1995. Mutagenicity of benzo[a]pyrene and dibenzopyrenes in the Salmonella typhimurium TM677 and the MCL-5 human cell forward mutation
assays. Mutat Res 342(1–2):9–16.
Buters JT, Mahadevan B, Quintanilla-Martinez L, Gonzalez FJ, Greim H, Baird WM, and Luch A.
2002. Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor formation. Chem Res Toxicol 15(9):1127–1135.
Chakravarti D, Pelling JC, Cavalieri EL, and Rogan EG. 1995. Relating aromatic hydrocarboninduced DNA adducts and c-H-ras mutations in mouse skin papillomas: The role of apurinic
sites. Proc Natl Acad Sci USA 92(22):10422–10426.
Chakravarti D, Mailander PC, Cavalieri EL, and Rogan EG. 2000. Evidence that error-prone DNA
repair converts dibenzo[a,l]pyrene-induced depurinating lesions into mutations: Formation,
clonal proliferation and regression of initiated cells carrying H-ras oncogene mutations in early
preneoplasia. Mutat Res 456(1–2):17–32.
Crump KS, Subramaniam RP, and Van Landingham CB. 2005. A numerical solution to the nonhomogeneous two-stage MVK model of cancer. Risk Anal 25(4):921–926.
Dashwood, R, Negishi T, Hayatsu H, Breinholt V, Hendricks J, and Bailey G. 1999. Chemopreventive
properties of chlorophylls towards aflatoxin B1: a review of the antimutagenicity and anticarcinogenicity data in rainbow trout. Carcinogenesis 20(10):1919–1926.
DeMarini DM, Hanley NM, Warren SH, Adams LD, and King LC. 2011. Association between mutation spectra and stable and unstable DNA adduct profiles in Salmonella for benzo[a]pyrene and
dibenzo[a,l]pyrene. Mutat Res 714(1–2):17–25.
FAO. 2011. Small-scale rainbow trout farming. FAO Fisheries and Aquaculture Technical Paper 561,
by Woynarovich A, Hoitsy G, and Moth-Poulsen T. United Nations Food and Agriculture
Program (FAO), Rome, Italy, p. 11.
Guttenplan JB, Kosinska W, Zhao ZL, Chen KM, Aliaga C, DelTondo J, Cooper T, Sun YW, Zhang SM,
Jiang K, Bruggeman R, Sharma AK, Amin S, Ahn K, and El-Bayoumy K. 2012. Mutagenesis and
carcinogenesis induced by dibenzo[a,l]pyrene in the mouse oral cavity: a potential new model
for oral cancer. Int J Cancer 130(12):2783–2790.
Higginbotham S, RamaKrishna NV, Johansson SL, Rogan EG, and Cavalieri EL. 1993. Tumor-initiating activity and carcinogenicity of dibenzo[a,l]pyrene versus 7,12-dimethylbenz [a]anthracene
and benzo[a]pyrene at low doses in mouse skin. Carcinogenesis 14:875–878.
Kushman ME, Kabler SL, Ahmad S, Doehmer J, Morrow CS, and Townsend AJ. 2007. Cytotoxicity and
mutagenicity of dibenzo[a,l]pyrene and (+/-)-dibenzo[a,l]pyrene-11,12-dihydrodiol in V79MZ
cells co-expressing either hCYP1A1 or hCYP1B1 together with human glutathione-S-transferase
A1. Mutat Res 624(1-2):80–87.
Lagerqvist A, Håkansson D, Prochazka G, Lundin C, Dreij K, Segerbäck D, Jernström B, Törnqvist M,
Seidel A, Erixon K, and Jenssen D. 2008. Both replication bypass fidelity and repair efficiency
influence the yield of mutations per target dose in intact mammalian cells induced by
benzo[a]pyrene-diol-epoxide and dibenzo[a,l]pyrene-diol-epoxide. DNA Repair (Amst)
7(8):1202–1212.
Lemieux CL, Douglas GR, Gingerich J, Phonethepswath S, Torous DK, Dertinger SD, Phillips DH,
Arlt VM, and White PA. 2011. Simultaneous measurement of benzo[a]pyrene-induced Pig-a and
lacZ mutations, micronuclei and DNA adducts in Muta™ Mouse. Environ Molec Mutagen
52(9):756–765.

401

https://scholarworks.umass.edu/dose_response/vol12/iss3/5

16

Bogen: Models Fit to ED001 Tumor Data

K. T. Bogen
Leubeck EG, Heidenreich WF, Hazelton WD, Paretzke HG, and Moolgavkar SH. 1999. Biologically
based analysis of the data for the Colorado uranium miners cohort: Age, dose and dose-rate
effects. Radiat Res 152:339–351.
Mahadevan B, Luch A, Bravo CF, Atkin J, Steppan LB, Pereira C, Kerkvliet NI, and Baird WM. 2005.
Dibenzo[a,l]pyrene induced DNA adduct formation in lung tissue in vivo. Cancer Lett
227(1):25–32.
Meschini R, Berni A, Marotta E, Filippi S, Fiore M, Mancinelli P, Natarajan AT, and Palitti F. 2010.
DNA repair mechanisms involved in the removal of DBPDE-induced lesions leading to chromosomal alterations in CHO cells. Cytogenet Genome Res 128(1-3):124–130.
Moolgavkar SH, and Knudson AG Jr. 1981. Mutation and cancer: A model for human carcinogenesis. J Natl Cancer Inst; 66:1037–1052.
Moolgavkar SH. 1983. Model for human carcinogenesis: Action of environmental agents. Environ
Health Perspect 50:285–291.
Moolgavkar SH. 1988. Biologically motivated two-stage model for cancer risk assessment. Toxicol Lett
43:139–150.
Moolgavkar S, and Luebeck G. 1990. Two-event model for carcinogenesis: Biological, mathematical,
and statistical considerations. Risk Anal 10:323–341.
Moolgavkar SH, and Venzon DJ. 1979. Two-event models for carcinogenesis: Incidence curves for
childhood and adult tumors. Math Biosci 47:55–77.
Moolgavkar SH, Dewanji A, and Venzon DJ. 1988. A stochastic two-stage model for cancer risk assessment. 1. The hazard function and the probability of tumor. Risk Anal 8:383–392.
Moolgavkar SH, Dewanji A, and Luebeck G. 1989. Cigarette smoking and lung cancer: A reanalysis
of the British doctors’ data. JNCI 81:415–420.
Mourón SA, Grillo CA, Dulout FN, and Golijow CD. 2006. Genotoxic effects of benzo[a]pyrene and
dibenzo[a,l]pyrene in a human lung cell line. Int J Toxicol 25(1):49–55.
Nesnow S, Davis C, Nelson G, Ross JA, Allison J, Adams L, and King LC. 1997. Comparison of the
morphological transforming activities of dibenzo[a,l]pyrene and benzo[a]pyrene in
C3H10T1/2CL8 cells and characterization of the dibenzo[a,l]pyrene-DNA adducts.
Carcinogenesis 18(10):1973–1978.
Nesnow S, Davis C, Padgett WT, Adams L, Yacopucci M, and King LC. 2000. 8,9-dihydroxy-8,9-dihydrodibenzo[a,l]pyrene is a potent morphological cell-transforming agent in
C3H10T(1)/(2)Cl8 mouse embryo fibroblasts in the absence of detectable stable covalent DNA
adducts. Carcinogenesis 21(6):1253–1257.
NRC. 1994. Science and judgment in risk assessment. National Research Council (NRC). National
Academies Press, Washington, DC.
O’Brien J, Renwick AG, Constable A, Dybing E, Müller DJ, Schlatter J, Slob W, Tueting W, van
Benthem J, Williams GM, and Wolfreys A. 2006. Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal. Food Chem Toxicol 44(10):1613–1635.
Plísková M, Vondrácek J, Vojtesek B, Kozubík A, and Machala M. 2005. Deregulation of cell proliferation by polycyclic aromatic hydrocarbons in human breast carcinoma MCF-7 cells reflects both
genotoxic and nongenotoxic events. Toxicol Sci 83(2):246–256.
Prahalad AK, Ross JA, Nelson GB, Roop BC, King LC, Nesnow S, and Mass MJ. 1997.
Dibenzo[a,l]pyrene-induced DNA adduction, tumorigenicity, and Ki-ras oncogene mutations in
strain A/J mouse lung. Carcinogenesis 18(10):1955–1563.
Press WH, Teukolsky SA, Vetterling WT, and Flannery BP. 1986. Numerical Recipes. Cambridge
University Press, New York, NY, p. 521–528.
Reddy AP, Harttig U, Barth MC, Baird WM, Schimerlik M, Hendricks JD, and Bailey GS. 1999a.
Inhibition of dibenzo[a,l]pyrene-induced multi-organ carcinogenesis by dietary chlorophyllin
in rainbow trout. Carcinogenesis 20(10):1919–1926.
Reddy AP, Spitsbergen JM, Mathews C, Hendricks JD, and Bailey GS. 1999b. Experimental hepatic
tumorigenicity by environmental hydrocarbon dibenzo[a,l]pyrene. J Environ Pathol Toxicol
Oncol 18(4):261–269.
Schober W, Luch A, Soballa VJ, Raab G, Stegeman JJ, Doehmer J, Jacob J, and Seidel A. 2006. On the
species-specific biotransformation of dibenzo[a,l]pyrene. Chem Biol Interact 161(1):37–48.
Topinka J, Marvanová S, Vondrácek J, Sevastyanova O, Nováková Z, Krcmár P, Pencíková K, and
Machala M. 2008. DNA adducts formation and induction of apoptosis in rat liver epithelial
‘stem-like’ cells exposed to carcinogenic polycyclic aromatic hydrocarbons. Mutat Res
638(12):122–132.

402

Published by ScholarWorks@UMass Amherst, 2014

17

Dose-Response: An International Journal, Vol. 12 [2014], Iss. 3, Art. 5

Models Fit to ED001 Tumor Data
U.S. EPA. 1976. Health Risk and Economic Impact Assessments of Suspected Carcinogens: Interim
Procedures & Guidelines. Federal Register 47(102, May 25):21402–21405. U.S. Environmental
Protection Agency (EPA), National Center for Environmental Assessment, Washington, DC.
U.S. EPA. 1986. Guidelines for Carcinogen Risk Assessment. EPA/630/R-00/004, September 1986.
Federal Register 51(185, September 24):33992–34003. U.S. Environmental Protection Agency
(EPA), Risk Assessment Forum, Washington, DC.
U.S. EPA. 2005. Guidelines for carcinogen risk assessment. EPA/630/P-03/001F, March 2005. U.S.
Environmental Protection Agency (EPA), Risk Assessment Forum, Washington, DC.
U.S. EPA. 2007. Framework for Determining a Mutagenic Mode of Action for Carcinogenicity: Using
EPA’s 2005 Cancer Guidelines and Supplemental Guidance for Assessing Susceptibility from
Early-Life Exposure to Carcinogens. EPA 120/R-07/002-A, September 2007. U.S.
Environmental Protection Agency (EPA), Risk Assessment Forum Technical Panel on
Mutagenic Mode of Action, Washington, DC.
Williams DE. 2012. The rainbow trout liver cancer model: response to environmental chemicals and
studies on promotion and chemoprevention. Comp Biochem Physiol C Toxicol Pharmacol
155(1):121–127.
Williams DE, Bailey GS, Reddy A, Hendricks JD, Oganesian A, Orner GA, Pereira CB, and Swenberg
JA. 2003. The rainbow trout (Oncorhynchus mykiss) tumor model: recent applications in lowdose exposures to tumor initiators and promoters. Toxicol Pathol 31 Suppl:58–61.
Williams DE, Orner G, Willard KD, Tilton S, Hendricks JD, Pereira C, Benninghoff AD, and Bailey
GS. 2009. Rainbow trout (Oncorhynchus mykiss) and ultra-low dose cancer studies. Comp
Biochem Physiol C Toxicol Pharmacol 149(2):175–181.
Wolfram Research. 2013. Wolfram Mathematica 9 Documentation Center. Wolfram Research, Inc.,
Champaign, IL. http://reference.wolfram.com/mathematica/guide/Mathematica.html
(www.wolfram.com).
Yoon JH, Besaratinia A, Feng Z, Tang MS, Amin S, Luch A, and Pfeifer GP. 2004. DNA damage, repair,
and mutation induction by (+)-Syn and (-)-anti-dibenzo[a,l]pyrene-11,12-diol-13,14-epoxides in
mouse cells. Cancer Res 64(20):7321–7328.
Zipperman M. 1999. Detecting apoptosis in carcinogen exposed trout livers. Bioresource Research
Thesis. Oregon State University, Corvallis, OR. http://ir.library.oregonstate.edu/xmlui/bitstream/handle/1957/7407/Zipperma.pdf?sequence=1

403

https://scholarworks.umass.edu/dose_response/vol12/iss3/5

18

